These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
196 related items for PubMed ID: 26831498
1. Phase I trial of nedaplatin chemotherapy concurrent with radiotherapy for untreated locoregionally advanced nasopharyngeal carcinoma. Liang Z, Wang S, Lin Z, Feng S, Cheng Z, Yang Y, Kuang Y, Fidelis C, Ullah S, Li F. Cancer Chemother Pharmacol; 2016 Mar; 77(3):643-51. PubMed ID: 26831498 [Abstract] [Full Text] [Related]
2. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Tang LQ, Chen DP, Guo L, Mo HY, Huang Y, Guo SS, Qi B, Tang QN, Wang P, Li XY, Li JB, Liu Q, Gao YH, Xie FY, Liu LT, Li Y, Liu SL, Xie HJ, Liang YJ, Sun XS, Yan JJ, Wu YS, Luo DH, Huang PY, Xiang YQ, Sun R, Chen MY, Lv X, Wang L, Xia WX, Zhao C, Cao KJ, Qian CN, Guo X, Hong MH, Nie ZQ, Chen QY, Mai HQ. Lancet Oncol; 2018 Apr; 19(4):461-473. PubMed ID: 29501366 [Abstract] [Full Text] [Related]
3. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer. Oshita F, Yamada K, Kato Y, Ikehara M, Noda K, Tanaka G, Nomura I, Suzuki R, Saito H. Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839 [Abstract] [Full Text] [Related]
4. Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity. Xu J, He X, Cheng K, Guo W, Bian X, Jiang X, Zhang L, Huang S. Head Neck; 2014 Oct; 36(10):1474-80. PubMed ID: 23996842 [Abstract] [Full Text] [Related]
5. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial. Ke LR, Xia WX, Qiu WZ, Huang XJ, Yang J, Yu YH, Liang H, Liu GY, Ye YF, Xiang YQ, Guo X, Lv X. BMC Cancer; 2017 Feb 15; 17(1):134. PubMed ID: 28202000 [Abstract] [Full Text] [Related]
6. Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Zheng J, Wang G, Yang GY, Wang D, Luo X, Chen C, Zhang Z, Li Q, Xu W, Li Z, Wang D. Jpn J Clin Oncol; 2010 May 15; 40(5):425-31. PubMed ID: 20085903 [Abstract] [Full Text] [Related]
7. Long-Term Results of Concurrent Chemoradiotherapy for Advanced N2-3 Stage Nasopharyngeal Carcinoma. Yin L, Bian XH, Wang X, Chen M, Wu J, Xu JH, Qian PD, Guo WJ, Jiang XS, Zhu HF, Gu JJ, Wu JF, Zhang YW, He X. PLoS One; 2015 May 15; 10(9):e0137383. PubMed ID: 26367317 [Abstract] [Full Text] [Related]
8. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: interim results from 2 prospective phase 2 clinical trials. Kong L, Hu C, Niu X, Zhang Y, Guo Y, Tham IW, Lu JJ. Cancer; 2013 Dec 01; 119(23):4111-8. PubMed ID: 24037893 [Abstract] [Full Text] [Related]
9. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Qiu F, Sun R, Chen QY, Huang PY, Luo DH, Hua YJ, Wu YS, Lv X, Wang L, Xia WX, Tang LQ, Ye YF, Chen MY, Guo X, Hong MH. Eur J Cancer; 2017 Apr 01; 75():14-23. PubMed ID: 28214653 [Abstract] [Full Text] [Related]
10. Radiotherapy combined docetaxel and oxaliplatin chemotherapy is effective in patients with locally advanced nasopharyngeal carcinoma. Pan F, Ruan Z, Li J, Pang X, Zhang Y, Zou L, Liang H. Med Oncol; 2015 Nov 01; 32(11):252. PubMed ID: 26471179 [Abstract] [Full Text] [Related]
11. The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma. Zhang L, Shan GP, Li P, Cheng PJ. Med Oncol; 2015 Mar 01; 32(3):41. PubMed ID: 25631634 [Abstract] [Full Text] [Related]
12. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials. Kong L, Zhang Y, Hu C, Guo Y, Lu JJ. Cancer; 2017 Jun 15; 123(12):2258-2267. PubMed ID: 28192641 [Abstract] [Full Text] [Related]
13. Phase I study of TPF neoadjuvant chemotherapy followed by radical radiotherapy in advanced nasopharyngeal carcinoma. Guo L, Lin HX, Xu M, Chen QY, Wang CT, Huang PY. Chin J Cancer; 2010 Feb 15; 29(2):136-9. PubMed ID: 20109339 [Abstract] [Full Text] [Related]
14. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J. Lancet Oncol; 2016 Nov 15; 17(11):1509-1520. PubMed ID: 27686945 [Abstract] [Full Text] [Related]
15. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J. Lancet Oncol; 2012 Feb 15; 13(2):163-71. PubMed ID: 22154591 [Abstract] [Full Text] [Related]
16. Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial. Tang C, Wu F, Wang R, Lu H, Li G, Liu M, Zhu H, Zhu J, Zhang Y, Hu K. Am J Cancer Res; 2016 Feb 15; 6(9):2064-2075. PubMed ID: 27725911 [Abstract] [Full Text] [Related]
17. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study. Wu F, Wang R, Lu H, Wei B, Feng G, Li G, Liu M, Yan H, Zhu J, Zhang Y, Hu K. Radiother Oncol; 2014 Jul 15; 112(1):106-11. PubMed ID: 24933452 [Abstract] [Full Text] [Related]
18. Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea. Park KH, Kim JS, Park Y, Seo HY, Park YJ, Choi IK, Oh SC, Seo JH, Kim CY, Jung KY, Shin SW, Kim YH, Kim JS, Lee NJ. Cancer Chemother Pharmacol; 2010 Sep 15; 66(4):643-51. PubMed ID: 20033411 [Abstract] [Full Text] [Related]
19. Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma. Jin T, Chen XZ, Liu JJ. Oncol Lett; 2015 Aug 15; 10(2):1123-1130. PubMed ID: 26622637 [Abstract] [Full Text] [Related]
20. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Wu X, Huang PY, Peng PJ, Lu LX, Han F, Wu SX, Hou X, Zhao HY, Huang Y, Fang WF, Zhao YY, Xue C, Hu ZH, Zhang J, Zhang JW, Ma YX, Liang WH, Zhao C, Zhang L. Ann Oncol; 2013 Aug 15; 24(8):2131-6. PubMed ID: 23661293 [Abstract] [Full Text] [Related] Page: [Next] [New Search]